Nektar Therapeutics (NKTR) Capital Leases (2010 - 2017)

Nektar Therapeutics' Capital Leases history runs 8 years deep, the most recent figure standing at $1.1 million for Q2 2017.

• In Q2 2017, Capital Leases fell 61.68% year-over-year to $1.1 million; the TTM figure through Jun 2017 stood at $1.1 million (down 61.68% YoY), while the FY2016 annual figure was $2.2 million, up 107.18% from the prior year.
• Capital Leases for Q2 2017 stood at $1.1 million, down from $1.6 million in the prior quarter.
• The five-year high for Capital Leases was $10.8 million in Q1 2013, with the low at $1.1 million in Q2 2017.
• The 5-year median for Capital Leases is $3.7 million (2014), against an average of $4.6 million.
• The sharpest annual moves came in 2015 and 2016: Capital Leases sank 75.0% in 2015, then surged 107.18% in 2016.
• Nektar Therapeutics' Capital Leases stood at $8.0 million in 2013, then slumped by 48.58% to $4.1 million in 2014, then sank by 74.08% to $1.1 million in 2015, then soared by 107.18% to $2.2 million in 2016, then sank by 52.5% to $1.1 million in 2017.
• Business Quant data shows NKTR's Capital Leases at $1.1 million in Q2 2017, $1.6 million in Q1 2017, and $2.2 million in Q4 2016.